Blog

Enveda Biosciences has raised $311 million to drive AI-based drug development, focusing on nature-derived treatments for skin issues and weight management.

Vijay Pande discusses his shift from a16z to VZVC, emphasizing smaller bets, the engineering mindset in biotech, and the importance of open datasets for AI in medicine.

The use of AI to create new viruses raises potential benefits for combating antibiotic resistance, but it also triggers urgent ethical and regulatory concerns.

SandboxAQ is changing drug discovery by making advanced models accessible through Claude, allowing researchers without PhDs to innovate faster.

The rise of hackable robot lawn mowers and Meta's encrypted DM removal highlight growing cybersecurity concerns in today's tech landscape.

Tokyo is set to become the premier tech destination of 2026 with the SusHi Tech Tokyo event, showcasing key technology domains and innovations.

Anthropic's $400M acquisition of Coefficient Bio marks a pivotal moment, blending AI and biotechnology for future healthcare innovations.

Mantis Biotech is pioneering digital twins of humans to address healthcare data issues, enabling personalized treatment and enhanced medical predictions.

Swann Communications is leveraging Amazon Bedrock to integrate generative AI into millions of IoT devices, enhancing notification filtering while addressing ethical concerns.

ByteDance's Protenix-v1 aims to rival AlphaFold3 in biomolecular structure prediction. This open-source model could democratize access and accelerate biotech innovations.

AI is transforming how we approach rare diseases by addressing labor shortages in drug discovery and treatment, as seen at Web Summit Qatar.